Next Science Ltd (ASX: NXS) Share Price and News

Mr Hummel has been a partner of a major Australian law firm for over fifteen years. He has experience with corporate and commercial transactions, with particular expertise in advising primary care, allied health, medical device and life science clients. Mr Hummel has been a non-executive director of GLG Corp Ltd since 2018 and serves as the Chair of GLG's Nomination and Remuneration Committee and as a member of GLG's Audit and Risk Committee.

Mr Spira is the CEO of iNova Pharmaceuticals (since 2017) which is a leading multinational consumer healthcare and pharmaceutical company with operations across Asia Pacific and Africa. Previously he was at Bausch Health (2011-2015) as Vice President and GM-North America (with responsibility for a portfolio of businesses spanning Vision Care, Dermatology and Aesthetic Devices) and was also Managing Director, Pacific region. Prior to that, Mr Spira spent over 15 years at Johnson & Johnson Inc in various roles including Vice President, Country Manager, Chief Marketing Officer and other sales and marketing roles across the Asia Pacific, Europe/Middle East and North American regions.

Prior to joining Next Science, Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms.

Ms Ostin is a non-executive director and audit and risk committee chair. Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017. During her 24 years with KPMG, Ms Ostin worked in Australia, the US, Asia, and the UK. Ms Ostin currently serves as a Non-Executive Director of 3P Learning Limited (ASX:3PL), dusk Group Limited (ASX:DSK), Capral Limited (ASX:CAA) and Alex Corporation Limited.

Mr Hall has 28 years in the global medical device industry, I.V. has held general management roles including product development, global strategic marketing, commercial operations, and sales leadership. I.V. joined DePuy Synthes, a subsidiary of Johnson and Johnson (NYSE: JNJ) in 1997 where he held senior roles including: Global Vice President - MedTech R&D and Worldwide President Trauma, Extremities, Craniomaxillofacial & Animal Health. I.V. was most recently a member of the Global Leadership Team and R&D Leadership Team for DePuy Synthes and completed the launch of the first surgical robot developed by JNJ / DePuy Synthes. As Worldwide President of Trauma, Extremities, Craniomaxillofacial and Animal Health, I.V.

-

-

-

-